Biotech News

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Rani Therapeutics (RANI)Rani Therapeutics2026-03-19 20:05 ESTEarnings

SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the

Related news

RANIRani Therapeutics2026-05-15 20:05 EST

Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

RANIRani Therapeutics2026-03-26 20:06 EST

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

View all latest news

Rani Therapeutics

Rani Therapeutics is a drug-delivery company focused on oral delivery of biologics and other therapeutics. Its platform aims to replace injections with swallowable delivery.

Recent company news

RANIRani Therapeutics2026-08-04 12:00 EST

Rani Therapeutics Appoints Michelle Gilson to Board of Directors

RANIRani Therapeutics2026-07-20 20:05 EST

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RANIRani Therapeutics2026-07-15 12:00 EST

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

RANIRani Therapeutics2026-07-09 20:05 EST

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

RANIRani Therapeutics2026-06-29 12:00 EST

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

Stock data

Close: 0.78 USD
Market cap: 96.4M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States